Skip to main content
. 2007 Oct 1;204(10):2439–2448. doi: 10.1084/jem.20070404

Figure 5.

Figure 5.

Anticoagulant and cytoprotective activities of mouse APC variants. (A) Anticoagulant activity of recombinant mouse WT APC (Δ) and APC variants (230/231-APC [◊], 3K3A-APC [▪], and 5A-APC [*]) determined in vitro in plasma. (B) Profibrinolytic activity of WT APC (Δ) and APC variants (230/231-APC [◊], 3K3A-APC [▪], 5A-APC [*], and S360A-APC [□]). (C) Antiapoptotic activity of WT APC (Δ) and APC variants (3K3A-APC [▪] and 5A-APC [*]) in assays of staurosporin-induced (0.25 μM, 24 h) mouse endothelial cell apoptosis. (D) Antiinflammatory activity of WT APC (Δ), WT protein C zymogen (□), and 5A-APC (*) induced in mouse Raw264.7 macrophage-like cells. Data represent the mean ± SD. (E and F) APC effect on in vivo thrombin generation in endotoxin-challenged mice. Endotoxin-challenged mice (n = 6 per group) were infused with PBS (▴), 10 (•) or 2 (○) μg WT APC, or APC variants, and thrombin generation was determined at 2 h (E) and at 30 min (F) after APC infusion by measuring plasma levels of TAT complex. Administration of 2 μg 5A-APC did not significantly alter in vivo thrombin generation.